Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
Artelo Biosciences, a clinical-stage pharmaceutical company focusing on lipid-signaling pathways for various medical conditions, announced its participation in the Maxim Group 2024 Virtual Healthcare Summit. The event is scheduled for October 15-17, 2024.
CEO Gregory D. Gorgas will engage in a fireside chat with Jason McCarthy, Maxim's Senior MD and Head of Biotechnology Research analyst, on Wednesday, October 16, 2024, at 4:00 p.m. ET. Interested parties can access the webcast by registering at the provided link.
Artelo Biosciences (Nasdaq: ARTL) focuses on developing treatments for people living with cancer, pain, dermatologic and neurological conditions. This participation offers an opportunity for investors and interested parties to gain insights into the company's progress and future plans.
Artelo Biosciences, un'azienda farmaceutica in fase clinica che si concentra sui percorsi di segnalazione lipidica per diverse condizioni mediche, ha annunciato la sua partecipazione al Maxim Group 2024 Virtual Healthcare Summit. L'evento è programmato per dal 15 al 17 ottobre 2024.
Il CEO Gregory D. Gorgasmercoledì 16 ottobre 2024, alle 16:00 ET. Le parti interessate possono accedere al webcast registrandosi al link fornito.
Artelo Biosciences (Nasdaq: ARTL) si concentra sullo sviluppo di trattamenti per le persone affette da cancro, dolore, condizioni dermatologiche e neurologiche. Questa partecipazione offre un'opportunità agli investitori e alle parti interessate di ottenere informazioni sui progressi dell'azienda e sui piani futuri.
Artelo Biosciences, una compañía farmacéutica en etapa clínica que se centra en las vías de señalización lipídica para diversas condiciones médicas, anunció su participación en el Maxim Group 2024 Virtual Healthcare Summit. El evento está programado para el 15 al 17 de octubre de 2024.
El CEO Gregory D. Gorgas participará en una charla informal con Jason McCarthy, MD senior y jefe del análisis de investigación biotecnológica de Maxim, el miércoles 16 de octubre de 2024, a las 4:00 p.m. ET. Las partes interesadas pueden acceder a la transmisión web registrándose en el enlace proporcionado.
Artelo Biosciences (Nasdaq: ARTL) se centra en el desarrollo de tratamientos para personas que padecen cáncer, dolor, afecciones dermatológicas y neurológicas. Esta participación ofrece una oportunidad para que los inversores y partes interesadas obtengan información sobre los avances de la compañía y sus planes futuros.
아르텔로 바이오사이언스는 다양한 의학적 상태를 위한 지질 신호 경로에 집중하는 임상 단계 제약 회사로, 맥심 그룹 2024 가상 헬스케어 서밋에 참여한다고 발표했습니다. 이 행사는 2024년 10월 15일부터 17일까지 예정되어 있습니다.
CEO 그레고리 D. 고르가스는 맥심의 선임 MD이자 생명공학 연구 분석 책임자인 제이슨 맥카시와 함께 2024년 10월 16일 수요일 오후 4시 ET에 대담을 진행합니다. 관심 있는 부분은 제공된 링크를 통해 웹캐스트에 등록하여 접근할 수 있습니다.
아르텔로 바이오사이언스(Nasdaq: ARTL)는 암, 통증, 피부 및 신경학적 질환을 앓고 있는 사람들을 위한 치료법 개발에 집중하고 있습니다. 이번 참여는 투자자와 관심 있는 부분에게 회사의 진행 상황과 미래 계획에 대한 통찰을 제공하는 기회를 제공합니다.
Artelo Biosciences, une entreprise pharmaceutique en phase clinique axée sur les voies de signalisation lipidiques pour diverses conditions médicales, a annoncé sa participation au Maxim Group 2024 Virtual Healthcare Summit. L'événement est prévu pour le 15 au 17 octobre 2024.
Le PDG Gregory D. Gorgas participera à une discussion informelle avec Jason McCarthy, MD senior et responsable de l'analyse de recherche biotechnologique de Maxim, le mercredi 16 octobre 2024, à 16h00 ET. Les parties intéressées peuvent accéder au webcast en s'inscrivant via le lien fourni.
Artelo Biosciences (Nasdaq: ARTL) se concentre sur le développement de traitements pour les personnes vivant avec le cancer, la douleur, des conditions dermatologiques et neurologiques. Cette participation offre une opportunité aux investisseurs et aux parties intéressées de mieux comprendre les progrès de l'entreprise et ses projets futurs.
Artelo Biosciences, ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf lipidvermittelte Signalwege für verschiedene medizinische Zustände konzentriert, hat seine Teilnahme am Maxim Group 2024 Virtual Healthcare Summit angekündigt. Die Veranstaltung ist für den 15. bis 17. Oktober 2024 geplant.
CEO Gregory D. Gorgas wird am Mittwoch, den 16. Oktober 2024, um 16:00 Uhr ET ein Gespräch am Kamin mit Jason McCarthy, Senior MD und Leiter der Biotechnologieforschung bei Maxim, führen. Interessierte Parteien können auf das Webcast zugreifen, indem sie sich über den bereitgestellten Link registrieren.
Artelo Biosciences (Nasdaq: ARTL) konzentriert sich auf die Entwicklung von Behandlungen für Menschen, die an Krebs, Schmerzen, dermatologischen und neurologischen Erkrankungen leiden. Diese Teilnahme bietet Investoren und Interessierten die Möglichkeit, Einblicke in den Fortschritt des Unternehmens und seine zukünftigen Pläne zu gewinnen.
- None.
- None.
SOLANA BEACH, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that it will be participating in the Maxim Group 2024 Virtual Healthcare Summit being held October 15-17, 2024.
Gregory D. Gorgas, CEO of Artelo Biosciences, will be joining Jason McCarthy, Maxim’s Senior MD and Head of Biotechnology Research analyst, in a fireside chat on Wednesday, October 16, 2024 at 4:00 p.m. ET. The fireside chat will be available for webcast by registering at https://m-vest.com/events/healthcare-10152024.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
When is Artelo Biosciences (ARTL) participating in the Maxim Group Virtual Healthcare Summit?
What is the focus of Artelo Biosciences (ARTL)?
How can investors access the Artelo Biosciences (ARTL) fireside chat at the Maxim Group Summit?
Who will be interviewing the CEO of Artelo Biosciences (ARTL) at the Maxim Group Summit?
